Jean Bardenheier, MD
General Practice · Azusa, CANPI 1780620138
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 578 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,862 and has fallen 60.6% since, to $1,128 in 2025. Among general practice clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 578 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Amgen$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Pfizer$705
- AbbVie$668
- plus $5K from 29 others
What the payments were for
- Food & beverage$12,180100%
- Education$390%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 81 | $2,293 |
| Amgen(2 entities) | 68 | $1,253 |
| Novo Nordisk | 74 | $1,223 |
| Lilly USA, LLC | 53 | $1,175 |
| Pfizer | 37 | $705 |
| AbbVie(2 entities) | 58 | $668 |
| Boehringer Ingelheim | 27 | $602 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $509 |
| GSK | 11 | $343 |
| E.r. Squibb & Sons, L.L.C. | 11 | $331 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $330 |
| Johnson & Johnson | 13 | $318 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $297 |
| Sanofi-aventis U.S. LLC | 21 | $267 |
| Novartis | 11 | $250 |
| La Jolla Pharmaceutical Company | 2 | $248 |
| Arbor Pharmaceuticals, Inc. | 14 | $234 |
| Amarin Pharma, Inc. | 9 | $167 |
| Merck | 7 | $128 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Astellas Pharma US Inc | 6 | $121 |
| Biohaven Pharmaceuticals, Inc. | 4 | $100 |
| Exact Sciences | 4 | $87 |
| Sanofi Pasteur Inc. | 4 | $80 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $75 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Eisai Inc. | 2 | $37 |
| Abbott | 2 | $28 |
| Dexcom, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $20 |
| Bayer | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Vertiflex, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,219 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 135 | $153,047 |
| Xigduo XrDapaglifloz Propaned/Metformin | 137 | $112,489 |
| OzempicSemaglutide | 89 | $106,516 |
| EliquisApixaban | 100 | $97,295 |
| FarxigaDapagliflozin Propanediol | 70 | $72,972 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 57 | $59,944 |
| XareltoRivaroxaban | 50 | $53,210 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 43 | $48,827 |
| Repatha SureclickEvolocumab | 67 | $39,592 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $34,813 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 31 | $33,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $30,843 |
| JardianceEmpagliflozin | 20 | $29,122 |
| MyrbetriqMirabegron | 28 | $26,976 |
| JanuviaSitagliptin Phosphate | 22 | $23,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,175 | $166,192148 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,293 | $106,630101 claims |
| Novo NordiskOzempic | $1,223 | $106,51689 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta | $602 | $104,11889 claims |
| PfizerEliquis | $705 | $97,295100 claims |
| Johnson & JohnsonXarelto | $318 | $53,21050 claims |
| MerckJanuvia, Janumet Xr, Dulera | $128 | $49,86155 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $267 | $48,82743 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $343 | $44,11063 claims |
| Astellas Pharma US IncMyrbetriq | $121 | $26,97628 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $234 | $5,42412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in Azusa
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Frederic MollRedwood City$2.5M
- Bradley ChingUpland$1.4M
- Eric BrassTorrance$755K
- Marc GeissbergerGreenbrae$583K
- Robert CampbellLong Beach$501K
- Varo BoyerNorth Hills$482K
- Michael MiyasakiSacramento$464K
- Apolinar MadrigalCeres$419K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.